WO2018085050A1 - Compositions et procédés pour l'imagerie de tissus et de tumeurs - Google Patents

Compositions et procédés pour l'imagerie de tissus et de tumeurs Download PDF

Info

Publication number
WO2018085050A1
WO2018085050A1 PCT/US2017/057357 US2017057357W WO2018085050A1 WO 2018085050 A1 WO2018085050 A1 WO 2018085050A1 US 2017057357 W US2017057357 W US 2017057357W WO 2018085050 A1 WO2018085050 A1 WO 2018085050A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
subject
tracer
tissue
seq
Prior art date
Application number
PCT/US2017/057357
Other languages
English (en)
Inventor
Gary Braun
Xiangyou LIU
Kazuki Sugahara
Erkki Ruoslahti
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of WO2018085050A1 publication Critical patent/WO2018085050A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1884—Nanotubes, nanorods or nanowires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

L'invention concerne des compositions et des procédés pour l'imagerie de tissus et de tumeurs in vivo avec un traceur qui peut être dissous ou rendu inactif par un agent d'attaque chimique pour augmenter la différence de concentration du traceur dans un tissu/tumeur d'intérêt et de concentration dans d'autres tissus/tumeurs et le sang.
PCT/US2017/057357 2016-11-03 2017-10-19 Compositions et procédés pour l'imagerie de tissus et de tumeurs WO2018085050A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416885P 2016-11-03 2016-11-03
US62/416,885 2016-11-03

Publications (1)

Publication Number Publication Date
WO2018085050A1 true WO2018085050A1 (fr) 2018-05-11

Family

ID=60452720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/057357 WO2018085050A1 (fr) 2016-11-03 2017-10-19 Compositions et procédés pour l'imagerie de tissus et de tumeurs

Country Status (2)

Country Link
TW (1) TW201834699A (fr)
WO (1) WO2018085050A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114045168A (zh) * 2021-11-19 2022-02-15 复旦大学 一种水溶性合金量子点纳米酶及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074434A2 (fr) * 2003-01-31 2004-09-02 Immunomedics, Inc. Methodes et compositions permettant d'administrer des agents therapeutiques et diagnostiques
US20100322862A1 (en) 2009-06-22 2010-12-23 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US20110262347A1 (en) 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074434A2 (fr) * 2003-01-31 2004-09-02 Immunomedics, Inc. Methodes et compositions permettant d'administrer des agents therapeutiques et diagnostiques
US20100322862A1 (en) 2009-06-22 2010-12-23 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US20110262347A1 (en) 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds

Non-Patent Citations (56)

* Cited by examiner, † Cited by third party
Title
AGUIRRE ET AL., GENE DEV, vol. 17, 2003, pages 3112 - 3126
ALTINOGLU ET AL.: "Wiley Interdiscip Rev Nanomed Nanobiotech", vol. 2, 2010, pages: 461 - 477
BARRETO ET AL., ADV MATER, vol. 23, 2011, pages H18 - H40
BOULDING ET AL., LANCET, vol. 270, 1957, pages 985
BRAUN ET AL., NAT MATER, vol. 13, 2014, pages 904 - 911
CARNAZZA ET AL., BIOSENSORS AND BIOELECTRONICS, vol. 23, 2008, pages 1137 - 1144
CASEY J L ET AL: "CLEARANCE OF YTTRIUM-90-LABELLED ANTI-TUMOR ANTIBODIES WITH ANTIBODIES RAISED AGAINST THE 12N4 DOTA MACROCYCLE", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 78, no. 10, 1 November 1998 (1998-11-01), pages 1307 - 1312, XP000986994, ISSN: 0007-0920 *
CHEN ET AL., NAT MATER, vol. 12, 2013, pages 445 - 451
CHEN ET AL., PLOS ONE, vol. 8, no. 12, 2013, pages e83805
CHOI ET AL., NAT BIOTECHNOL, vol. 25, 2007, pages 1165 - 1170
CHOI ET AL., NAT NANOTECHNOL, vol. 5, 2010, pages 42 - 47
FAN ET AL., PHARM RES, vol. 24, 2007, pages 868 - 879
GAO ET AL., BIOCONJUGATE CHEM, vol. 21, 2010, pages 604 - 609
HAK SOO CHOI ET AL: "Design considerations for tumour-targeted nanoparticles", NATURE NANOTECHNOLOGY, vol. 5, no. 1, 1 November 2009 (2009-11-01), GB, pages 42 - 47, XP055444144, ISSN: 1748-3387, DOI: 10.1038/nnano.2009.314 *
HAMZAH ET AL., PROC NATL ACAD SCI USA, vol. 108, 2011, pages 7154 - 7159
HATCHER ET AL., FUTURE MEDICINAL CHEMISTRY, vol. 1, 2009, pages 1643 - 1670
HE ET AL., SCI REP, vol. 3, 2013
HELDIN ET AL., NAT REV CANCER, vol. 4, 2004, pages 806 - 813
HOCKETT ET AL., ENVIRON TOXICOL CHEM, vol. 15, 1996, pages 1687 - 1693
JIANG ET AL., PROC NATL ACAD SCI, vol. 101, 2004, pages 17867 - 17872
JOKERST ET AL., NANOMEDICINE, vol. 6, 2011, pages 715 - 728
KAZUKI N. SUGAHARA ET AL: "A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis", JOURNAL OF CONTROLLED RELEASE, vol. 212, 1 August 2015 (2015-08-01), NL, pages 59 - 69, XP055444180, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.06.009 *
KOIVUNEN ET AL., JBIOL CHEM, vol. 268, 1993, pages 20205 - 20210
LI ET AL., CANCER RES, vol. 42, 1982, pages 999 - 1004
LI-HUA JIN ET AL: "Ultrasensitive and Selective Fluorimetric Detection of Copper Ions Using Thiosulfate-Involved Quantum Dots", ANALYTICAL CHEMISTRY, vol. 86, no. 15, 5 August 2014 (2014-08-05), US, pages 7209 - 7213, XP055444667, ISSN: 0003-2700, DOI: 10.1021/ac501515f *
LIU ET AL., ADV FUND MATER, vol. 26, 2016, pages 267 - 276
MAEDA ET AL., INT IMMUNOPHARMACOL, vol. 3, 2003, pages 319 - 328
MANN ET AL., NATURE COMM., vol. 7, 2016, pages 11980
MENGXIAO YU ET AL: "Clearance Pathways and Tumor Targeting of Imaging Nanoparticles", ACS NANO, vol. 9, no. 7, 28 July 2015 (2015-07-28), US, pages 6655 - 6674, XP055444153, ISSN: 1936-0851, DOI: 10.1021/acsnano.5b01320 *
MITCHEM ET AL., CANCER RES, vol. 73, 2013, pages 1128 - 1141
NOMURA ET AL., JNUCIMED, vol. 55, 2014, pages 845 - 851
PANG ET AL., J CONTROL RELEASE, vol. 175, 2014, pages 48 - 53
PANG ET AL., NAT COMMUN, vol. 5, 2014, pages 4904
PASCH ET AL., KIDNEY INT, vol. 74, 2008, pages 1444 - 1453
RAJOTTE ET AL., J CLIN INVEST, vol. 102, 1998, pages 430 - 437
S. NOMURA ET AL: "PET Imaging Analysis with 64Cu in Disulfiram Treatment for Aberrant Copper Biodistribution in Menkes Disease Mouse Model", THE JOURNAL OF NUCLEAR MEDICINE, vol. 55, no. 5, 1 May 2014 (2014-05-01), US, pages 845 - 851, XP055444159, ISSN: 0161-5505, DOI: 10.2967/jnumed.113.131797 *
SANTNER ET AL., BREAST CANCER RES TR, vol. 65, 2001, pages 101 - 110
SIMON-GRACIA ET AL., BIOMATERIALS, vol. 104, 2016, pages 247 - 257
SUGAHARA ET AL., CANCER CELL, vol. 16, 2009, pages 510 - 520
SUGAHARA ET AL., J CONTROL RELEASE, vol. 212, 2015, pages 59 - 69
SUGAHARA ET AL., SCIENCE, vol. 328, 2010, pages 1031 - 1035
SUGARBAKER ET AL., CANCER TREAT REV, vol. 48, 2016, pages 42 - 49
TAVITIAN ET AL.: "Textbook of in vivo Imaging in Vertebrates", 2007, JOHN WILEY & SONS, LTD.
TEESALU ET AL., FRONT ONCOL, vol. 3, 2013, pages 216
TEESALU ET AL., PROC NATL ACAD SCI USA, vol. 106, 2009, pages 16157 - 16162
TEESALU ET AL., PROC NATL ACAD SCI, vol. 106, 2009, pages 16157 - 16162
WEGNER ET AL., CHEM SOC REV, vol. 44, 2015, pages 4792 - 4834
WU ET AL., EXPERT OPIN DRUG MET, vol. 9, 2013, pages 1265 - 1277
XIANGYOU LIU ET AL: "In vivo cation exchange in quantum dots for tumor-specific imaging", NATURE COMMUNICATIONS, vol. 8, no. 1, 24 August 2017 (2017-08-24), XP055444196, DOI: 10.1038/s41467-017-00153-y *
YERRAM ET AL., CLIN JAM SOC NEPHRO, vol. 2, 2007, pages 258 - 263
YIN ET AL., CHINESE PHYS B, vol. 21, 2012, pages 116101
ZHANG ET AL., BIOMATERIALS, vol. 34, 2013, pages 3639 - 3646
ZHANG Y ET AL: "Improving the visualization of fluorescently tagged nanoparticles and fluorophore-labeled molecular probes by treatment with CuSO4 to quench autofluorescence in the rat inner ear", HEARING RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 269, no. 1-2, 1 October 2010 (2010-10-01), pages 1 - 11, XP027261278, ISSN: 0378-5955, [retrieved on 20100724] *
ZONGHAI SHENG ET AL: "Cation exchange in aptamer-conjugated CdSe nanoclusters: a novel fluorescence signal amplification for cancer cell detection - Supporting information", CHEMICAL COMMUNICATIONS, vol. 48, no. 35, 1 January 2012 (2012-01-01), pages 4202, XP055444205, ISSN: 1359-7345, DOI: 10.1039/c2cc00033d *
ZONGHAI SHENG ET AL: "Cation exchange in aptamer-conjugated CdSe nanoclusters: a novel fluorescence signal amplification for cancer cell detection", CHEMICAL COMMUNICATIONS, vol. 48, no. 35, 1 January 2012 (2012-01-01), pages 4202 - 4204, XP055444208, ISSN: 1359-7345, DOI: 10.1039/c2cc00033d *
ZRAZHEVSKIY ET AL., NAT COMMUN, vol. 4, 2013, pages 1619

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114045168A (zh) * 2021-11-19 2022-02-15 复旦大学 一种水溶性合金量子点纳米酶及其制备方法和应用
CN114045168B (zh) * 2021-11-19 2023-09-05 复旦大学 一种水溶性合金量子点纳米酶及其制备方法和应用

Also Published As

Publication number Publication date
TW201834699A (zh) 2018-10-01

Similar Documents

Publication Publication Date Title
Liu et al. In vivo cation exchange in quantum dots for tumor-specific imaging
Shi et al. Tumor-targeting CuS nanoparticles for multimodal imaging and guided photothermal therapy of lymph node metastasis
Yu et al. Tumor microenvironment-triggered fabrication of gold nanomachines for tumor-specific photoacoustic imaging and photothermal therapy
Han et al. Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma
Ruan et al. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer
Choi et al. Inorganic–inorganic nanohybrids for drug delivery, imaging and photo-therapy: recent developments and future scope
ES2792062T3 (es) Tratamientos contra el cáncer
Meng et al. Functional metal–organic framework-based nanocarriers for accurate magnetic resonance imaging and effective eradication of breast tumor and lung metastasis
Song et al. Iodine-131-labeled, transferrin-capped polypyrrole nanoparticles for tumor-targeted synergistic photothermal-radioisotope therapy
Zheng et al. Two-stage activated nano-truck enhanced specific aggregation and deep delivery for synergistic tumor ablation
Zhai et al. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy
Wei et al. TMTP1-modified indocyanine green-loaded polymeric micelles for targeted imaging of cervical cancer and metastasis sentinel lymph node in vivo
Nagaya et al. Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination
Wang et al. Tumor-microenvironment triggered signal-to-noise boosting nanoprobes for NIR-IIb fluorescence imaging guided tumor surgery and NIR-II photothermal therapy
US20200171165A1 (en) Enhanced targeted delivery of therapeutic agents
US20230390394A1 (en) Bismuth-Gadolinium Nanoparticles
CN111587126A (zh) 组合剂型和用于验证的造影剂毒性最小化方案
Liu et al. Biomineralization-inspired dasatinib nanodrug with sequential infiltration for effective solid tumor treatment
Zhang et al. A bioenvironment-responsive versatile nanoplatform enabling rapid clearance and effective tumor homing for oxygen-enhanced radiotherapy
Gao et al. In vivo biodistribution and passive accumulation of upconversion nanoparticles in colorectal cancer models via intraperitoneal injection
Juengpanich et al. Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer
Aragon-Sanabria et al. Ultrasmall nanoparticle delivery of doxorubicin improves therapeutic index for high-grade glioma
Han et al. Spatiotemporal tracking of gold nanorods after intranasal administration for brain targeting
Alifu et al. Retracted Article: A novel TMTP1-modified theranostic nanoplatform for targeted in vivo NIR-II fluorescence imaging-guided chemotherapy for cervical cancer
Wang et al. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17804324

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17804324

Country of ref document: EP

Kind code of ref document: A1